Jump to:
Mallory Ursul practices in the intellectual property transactions group and advises public and private companies, investors, entrepreneurs, and other clients on a wide range of strategic transactions, including license agreements, complex collaborations, mergers and acquisitions, supply and distribution agreements, and other commercial transactions where intellectual property is a key consideration. Mallory has represented clients in a variety of industries including life sciences, technology, software, and consumer products.
Experience
- Advised Novo Nordisk in a multi-year partnership with NanoVation Therapeutics to develop genetic medicines for rare and cardiometabolic diseases.
- Advised clinical stage precision cancer biopharmaceutical company IDRx in licensing transactions with Germany-based Merck KGaA and Blueprint Medicines to secure rights to IDRX-42 and IDRX-73- two small molecule tyrosine kinase inhibitors.
- Advised Ginkgo Bioworks, a horizontal platform for cell programming, in an agreement with Bayer to expand Ginkgo’s platform capabilities in agricultural biologicals.